Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 3Phase 2 1

Status

Recruiting 4Completed 2

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 6

Conditions

Neoplasms 1520Carcinoma, Non-Small-Cell Lung 754Breast Neoplasms 572Neoplasm Metastasis 529Colorectal Neoplasms 445Melanoma 391Leukemia, Myeloid, Acute 371Multiple Myeloma 363Ovarian Neoplasms 352Recurrence 336Lymphoma 334Advanced Solid Tumors 324Lymphoma, Non-Hodgkin 314Prostatic Neoplasms 300Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 232Carcinoma, Renal Cell 225Squamous Cell Carcinoma of Head and Neck 210Lung Neoplasms 210Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 183Solid Tumors 182Carcinoma, Hepatocellular 164Hematologic Neoplasms 155Head and Neck Neoplasms 152Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Interventions

sintilimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Advanced Lung Cancer × Clear all
NCT06945523 2025-06-04

Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer

Chongqing Precision Biotech Co., Ltd

Phase 1 Recruiting
60 enrolled
Thoracic

Advanced Lung Cancer

NCT06992583 2025-05-28

Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer

Chongqing Precision Biotech Co., Ltd

Phase 1 Recruiting
60 enrolled
Thoracic

Advanced Lung Cancer

NCT06903117 2025-04-03

Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma

Chongqing Precision Biotech Co., Ltd

Phase 1 Recruiting
60 enrolled
Thoracic

Advanced Lung Cancer

NCT06768151 2025-01-10

A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer

Chongqing Precision Biotech Co., Ltd

Phase 1 Recruiting
48 enrolled
Thoracic

Advanced Lung Cancer

NCT04672356 2023-06-22

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
19 enrolled
Thoracic

Advanced Lung Cancer

NCT04672369 2023-06-22

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
42 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡